EUVIMEDEUVIMED entdecken
Multizentrische Studie

Distinct Cancer Risk Profiles in Patients With Systemic Sclerosis With Autoantibody Stratification

Arjun Mahajan iD, Maria Vazquez-Machado, Nikki Zangenah, Jeffrey A Sparks iD, Avery H LaChance

Arthritis & Rheumatology · 2026-03 · 78 (3) · 705-712

DOI: 10.1002/art.43339 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 14.11.2025. Verfasst von Arjun Mahajan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Autoantibodies, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Rheumatology Research Foundation, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Patients with systemic sclerosis (SSc) face increased cancer risk compared to the general population, yet current evidence on specific cancer patterns and their relationship to autoantibody status remain poorly characterized. This study seeks to evaluate cancer risk patterns in patients with SSc and investigate associations between specific autoantibodies and cancer development.

Methods

This multicenter cohort study analyzed five‐year cancer incidences in 66,637 adults with SSc versus matched controls with seborrheic keratosis using electronic medical records from 128 health care organizations (from 2014 to 2024). Patients were stratified by autoantibody status (RNA polymerase III, anticentromere, or anti‐Scl‐70) when available. Primary outcomes included five‐year incidences of hematologic and solid‐organ cancers, with hazard ratios (HRs) calculated via Cox proportional hazards regression.

Results

Patients with SSc demonstrated elevated five‐year all‐type cancer risk (HR 1.17, 95% confidence interval [CI] 1.11–1.23). Hematologic cancer risk was significantly increased (HR 1.68, 95% CI 1.50–1.88), particularly for multiple myeloma (HR 2.13, 95% CI 1.61–2.81) and myelodysplastic syndromes (HR 2.03, 95% CI 1.49–2.77). For solid‐organ cancers (HR 1.23, 95% CI 1.16–1.31), esophageal cancer showed the highest risk (HR 3.96, 95% CI 2.36–6.65), followed by lung cancer (HR 2.32, 95% CI 2.00–2.69). Among autoantibody subgroups, patients with anti‐Scl‐70 positivity showed increased overall cancer risk (HR 1.40, 95% CI 1.03–1.92) and patients with RNA polymerase III positivity had higher rates of hematologic cancers (HR 2.20, 95% CI 1.10–4.28), whereas patients with anticentromere positivity demonstrated no increased cancer risks.

Conclusion

Patients with SSc demonstrate significantly increased risks for both hematologic and solid‐organ cancers, with risk profiles varying by autoantibody status. These findings suggest the need for targeted cancer screening strategies in SSc and further research to confirm the generalizability of these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicAutoantibodiesNeoplasmsHumansFemaleMiddle AgedMaleRNA Polymerase IIIAgedAdultIncidenceAntibodies, AntinuclearRisk FactorsCase-Control StudiesCohort StudiesHematologic Neoplasms

Substanzen

AutoantibodiesRNA Polymerase IIIAntibodies, Antinuclearanticentromere antibody

Autor:innen und Institutionen

  • Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Brigham and Women's Hospital, Boston, Massachusetts, and Ponce Health Science University School of Medicine, Ponce, Puerto Rico.
  • Brigham and Women's Hospital and Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.

ORCID-Profile: Arjun Mahajan, Jeffrey A Sparks

Förderung

  • Rheumatology Research Foundation
  • NIAMS NIH HHS

Zitieren

APA

Mahajan, A., Vazquez-Machado, M., Zangenah, N., Sparks, J. A., & LaChance, A. H. (2026). Distinct Cancer Risk Profiles in Patients With Systemic Sclerosis With Autoantibody Stratification. Arthritis & Rheumatology, 78(3), 705-712. https://doi.org/10.1002/art.43339

Vancouver

Mahajan A, Vazquez-Machado M, Zangenah N, Sparks JA, LaChance AH. Distinct Cancer Risk Profiles in Patients With Systemic Sclerosis With Autoantibody Stratification. Arthritis & Rheumatology. 2026;78(3):705-712. doi:10.1002/art.43339

BibTeX
@article{Mahajan2026,
  author = {Mahajan, Arjun and Vazquez-Machado, Maria and Zangenah, Nikki and Sparks, Jeffrey A and LaChance, Avery H},
  title = {Distinct Cancer Risk Profiles in Patients With Systemic Sclerosis With Autoantibody Stratification},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  volume = {78},
  number = {3},
  pages = {705--712},
  doi = {10.1002/art.43339}
}
Kostenlos starten →